Sector
Healthcare
Industry
Biotechnology
Employees
50
First IPO Date
June 25, 2021
| Name | Title | Pay | Year Born |
| Velichka Valcheva | Chief Executive Officer | 0 | 1975 |
| Aaron Cameron | Chief Operating Officer | 0 | 1985 |
| Florian Schonharting | Co-Founder & Non-Executive Chairman of the Board | 0 | 1969 |
| Magnus Halle | Co-Founder & MD of Ireland | 0 | 1997 |
| Julie Ryan | Vice President of Finance | 0 | 1986 |
GH Research PLC is a clinical-stage biopharmaceutical firm dedicated to creating novel therapies for psychiatric and neurological conditions. The company primarily concentrates on developing 5-Methoxy-N,N-Dimethyltryptamine (5-MeO-DMT) treatments, specifically targeting patients with treatment-resistant depression (TRD). Its most advanced program is GH001, an inhalable 5-MeO-DMT product candidate that has successfully completed two Phase 1 clinical trials and a subsequent Phase 1/2 clinical trial in TRD patients. Additionally, GH Research is developing GH002, an injectable 5-MeO-DMT candidate, and GH003, an intranasal 5-MeO-DMT candidate. Both GH002 and GH003 are currently in preclinical development, with a focus on their potential applications in various psychiatric and neurological disorders. Founded in 2018, GH Research PLC is headquartered in Dublin, Ireland.